Ameriprise
BMY.RT

Ameriprise’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ameriprise’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-180,174
Closed -$124K – 3951
2020
Q4 		$124K Sell
180,174
-19,695
-10% -$42K ﹤0.01% 3672
2020
Q3 		$450K Sell
199,869
-1,931
-1% -$5.51K ﹤0.01% 3281
2020
Q2 		$722K Sell
201,800
-14,884
-7% -$53.7K ﹤0.01% 3052
2020
Q1 		$822K Sell
216,684
-48,304
-18% -$159K ﹤0.01% 2912
2019
Q4 		$799K Buy
+264,988
New +$689K ﹤0.01% 3157

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Ameriprise's BMY.RT Position: Q1 2021 in Review

Ameriprise sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 180,174 shares — an estimated $124K sold.

Ameriprise first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $822K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Ameriprise reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Ameriprise sold 180,174 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $124K.
  • Ameriprise first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Ameriprise's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $822K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Ameriprise's 13F filing for Q1 2021, filed 17 May 2021.